Literature DB >> 27442082

LRP-1 Pathway Targeted Inhibition of Vascular Abnormalities in the Retina of Diabetic Mice.

Ahamed Hossain1, Lamiya Tauhid2, Ian Davenport1, Thomas Huckaba1, Richard Graves3, Tarun Mandal3, Syed Muniruzzaman1, Syed A Ahmed4, Partha S Bhattacharjee1.   

Abstract

PURPOSE: The cell surface LDL (low-density lipoprotein) receptor-related protein-1 (LRP-1) is important for lipid transport and several cell signaling processes. Human apolipoprotein E (apoE) is a ligand of LRP-1. We previously reported that a short peptide (apoEdp) mimicking the LRP-1 binding region of apoE prevents hyperglycemia-induced retinal endothelial cell dysfunction in vitro. The in-vivo outcome of apoE-based peptidomimetic inhibition of LRP-1 in the treatment of diabetic retinopathy is unknown.
METHODS: Six months after streptozotocin induction of diabetes, male C57Bl/6 mice were intravitreally inoculated with apoEdp in a controlled release formulation. On the 15th day post-apoEdp treatment, mouse retinas were harvested to examine (1) blood-retinal-barrier (BRB) permeability by Evans blue dye, inflammatory leukostasis by concanavalin staining of leukocytes and LRP-1 pathway-related protein expression by Western blot analysis and gelatin zymography.
RESULTS: Intravitreal apoEdp treatment of diabetic mice significantly reduced Evans blue extravasation and the number of adherent leukocytes in the diabetic mouse retinas. ApoEdp treatment inhibited the expression of extracellular matrix (ECM) degrading proteases heparanase and MMP-2, and restores the BRB tight junction proteins occludin and ZO-1. ApoEdp treatment also inhibited Wnt/β-catenin-related expression of pro-inflammatory molecules ICAM-1, HIF-1α, and VEGF through negative regulation by LRP-1.
CONCLUSION: Intravitreal apoEdp treatment of diabetic mice resulted a significant decrease in retinal vascular abnormalities through downregulation of LRP-1-related ECM protein degradation and Wnt/β-catenin-related pro-angiogenic molecules.

Entities:  

Keywords:  BRB; ECM; LRP-1; Wnt/β-catenin; diabetic retinopathy

Mesh:

Substances:

Year:  2016        PMID: 27442082      PMCID: PMC5499693          DOI: 10.1080/02713683.2016.1203441

Source DB:  PubMed          Journal:  Curr Eye Res        ISSN: 0271-3683            Impact factor:   2.424


  32 in total

1.  Preparation and characterization of rifampicin-PLGA microspheres/sodium alginate in situ gel combination delivery system.

Authors:  Chunhui Hu; Hanzhou Feng; Chunyan Zhu
Journal:  Colloids Surf B Biointerfaces       Date:  2012-03-03       Impact factor: 5.268

Review 2.  Diabetic Macular Edema: Pathophysiology and Novel Therapeutic Targets.

Authors:  Arup Das; Paul G McGuire; Sampathkumar Rangasamy
Journal:  Ophthalmology       Date:  2015-04-30       Impact factor: 12.079

3.  The receptor-binding region of human apolipoprotein E has direct anti-infective activity.

Authors:  Curtis B Dobson; Sean D Sales; Patrick Hoggard; Matthew A Wozniak; Keith A Crutcher
Journal:  J Infect Dis       Date:  2005-12-28       Impact factor: 5.226

4.  Local cellular sources of apolipoprotein E in the human retina and retinal pigmented epithelium: implications for the process of drusen formation.

Authors:  D H Anderson; S Ozaki; M Nealon; J Neitz; R F Mullins; G S Hageman; L V Johnson
Journal:  Am J Ophthalmol       Date:  2001-06       Impact factor: 5.258

5.  Decrease in LDL receptor-related protein expression and function correlates with advanced stages of Wilms tumors.

Authors:  Richard R Desrosiers; Marie-Eve Rivard; Paul E Grundy; Borhane Annabi
Journal:  Pediatr Blood Cancer       Date:  2006-01       Impact factor: 3.167

6.  The low density lipoprotein receptor-1, LRP1, interacts with the human frizzled-1 (HFz1) and down-regulates the canonical Wnt signaling pathway.

Authors:  Alona Zilberberg; Abraham Yaniv; Arnona Gazit
Journal:  J Biol Chem       Date:  2004-01-21       Impact factor: 5.157

7.  Heparanase Enhances Tumor Growth and Chemoresistance by Promoting Autophagy.

Authors:  Anna Shteingauz; Ilanit Boyango; Inna Naroditsky; Edward Hammond; Maayan Gruber; Ilana Doweck; Neta Ilan; Israel Vlodavsky
Journal:  Cancer Res       Date:  2015-08-06       Impact factor: 12.701

8.  A peptide inhibitor of the urokinase/urokinase receptor system inhibits alteration of the blood-retinal barrier in diabetes.

Authors:  Deepti Navaratna; Gina Menicucci; Joann Maestas; Ramprasad Srinivasan; Paul McGuire; Arup Das
Journal:  FASEB J       Date:  2008-06-16       Impact factor: 5.191

9.  Wnt signaling in age-related macular degeneration: human macular tissue and mouse model.

Authors:  Jingsheng Tuo; Yujuan Wang; Rui Cheng; Yichao Li; Mei Chen; Fangfang Qiu; Haohua Qian; Defen Shen; Rosana Penalva; Heping Xu; Jian-Xing Ma; Chi-Chao Chan
Journal:  J Transl Med       Date:  2015-10-17       Impact factor: 5.531

10.  Antagonizing Wnt pathway in diabetic retinopathy.

Authors:  Ling Zhao; Sherrina H Patel; Jacqueline Pei; Kang Zhang
Journal:  Diabetes       Date:  2013-12       Impact factor: 9.461

View more
  3 in total

1.  FVIII regulates the molecular profile of endothelial cells: functional impact on the blood barrier and macrophage behavior.

Authors:  Marie Cadé; Javier Muñoz-Garcia; Antoine Babuty; Louis Paré; Denis Cochonneau; Karim Fekir; Mathias Chatelais; Marie-Françoise Heymann; Anna Lokajczyk; Catherine Boisson-Vidal; Dominique Heymann
Journal:  Cell Mol Life Sci       Date:  2022-02-21       Impact factor: 9.261

2.  Loss of β-catenin via activated GSK3β causes diabetic retinal neurodegeneration by instigating a vicious cycle of oxidative stress-driven mitochondrial impairment.

Authors:  Xing-Sheng Shu; Huazhang Zhu; Xiaoyan Huang; Yangfan Yang; Dandan Wang; Yiling Zhang; Weizhen Zhang; Ying Ying
Journal:  Aging (Albany NY)       Date:  2020-06-23       Impact factor: 5.682

Review 3.  Wnt Signaling in Inner Blood-Retinal Barrier Maintenance.

Authors:  Felix Yemanyi; Kiran Bora; Alexandra K Blomfield; Zhongxiao Wang; Jing Chen
Journal:  Int J Mol Sci       Date:  2021-11-02       Impact factor: 6.208

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.